Multicenter, Open-label, Randomized Study to Evaluate Inhibition of Ovulation During Treatment With Three Transdermal Patch Formulations Containing 0.55 mg Ethinylestradiol (EE) and 2.10 mg Gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles.

Trial Profile

Multicenter, Open-label, Randomized Study to Evaluate Inhibition of Ovulation During Treatment With Three Transdermal Patch Formulations Containing 0.55 mg Ethinylestradiol (EE) and 2.10 mg Gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2014

At a glance

  • Drugs Ethinylestradiol/gestodene (Primary)
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 19 Apr 2012 Bayer HealthCare trial company and lead trial centre added as reported by European Clinical Trials Database record.
    • 17 Jan 2012 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
    • 09 Sep 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top